title: Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient.
abstract: The introduction of atypical antipsychotics into clinical practice has lead to an increase of adverse metabolic effects in psychotic patients. Amisulpride is a substituted benzamide derivative, and its use is associated with a lower risk of weight gain compared to other atypical antipsychotics. The case of an acute and excessive weight increase in a female first-episode schizophrenic patient who was treated with amisulpride monotherapy is reported. The improvement in psychopathology was remarkable. However, the patient gained 12.9 kg of body weight in the first 2 months of amisulpride administration and a total of 17.3 kg, 6 months after initiation of the treatment. Glucose and insulin levels, as well as a glucose tolerance test, remained normal throughout the observation period.
authors.affiliation: Department of Psychiatry, Athens University Medical School, Eginition Hospital, Athens, Greece. gnpapad@med.uoa.gr
authors.forename: George N
authors.initials: GN
authors.lastname: Papadimitriou
authors.forename: Christos G
authors.initials: CG
authors.lastname: Theleritis
authors.forename: Dimitris G
authors.initials: DG
authors.lastname: Dikeos
authors.forename: Constantin J
authors.initials: CJ
authors.lastname: Psarros
authors.forename: Constantin R
authors.initials: CR
authors.lastname: Soldatos
mesh_terms: D000328:Adult; D000077582:Amisulpride; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D013469:Sulpiride / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D013469:Sulpiride; D000077582:Amisulpride